title: Bioactive compounds from the Red Sea marine sponge Hyrtios species.
abstract: In continuation of our search for drug leads from Red Sea sponges we have investigated the ethyl acetate fraction of the organic extract of the Red Sea sponge Hyrtios species. Bioassay-directed fractionation of the active fraction resulted into the identification of three new alkaloids, hyrtioerectines D-F (1-3). Hyrtioerectines D-F belong to the rare marine alkaloids in which the indole and β-carboline fragments of the molecule are linked through C-3/C-3 of both moieties. The structures of the isolated compounds were established based on different spectroscopic data including UV, IR, 1D and 2D NMR (COSY, HSQC, and HMBC) and high-resolution mass spectral studies. The antimicrobial activity against several pathogens and the free radical scavenging activity of the compounds using DPPH reagent were evaluated. In addition, the growth inhibitory activity of the compounds against three cancer cell lines was also evaluated. Hyrtioerectines D-F (1-3) displayed variable antimicrobial, free radical scavenging and cancer growth inhibition activities. Generally, compounds 1 and 3 were more active than compound 2.
authors.affiliation: Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia. dyoussef@kau.edu.sa
authors.forename: Diaa T A
authors.initials: DT
authors.lastname: Youssef
authors.forename: Lamiaa A
authors.initials: LA
authors.lastname: Shaala
authors.forename: Hani Z
authors.initials: HZ
authors.lastname: Asfour
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D045744:Cell Line, Tumor; D016166:Free Radical Scavengers / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D019156:Indian Ocean; D026121:Indole Alkaloids / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D011161:Porifera / Q000737:chemistry*; D013057:Spectrum Analysis / Q000379:methods
chemical_list: D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D016166:Free Radical Scavengers; D026121:Indole Alkaloids; C585603:hyrtioerectine D; C585604:hyrtioerectine E; C585605:hyrtioerectine F
references.citation: J Nat Prod. 2002 Aug;65(8):1173-6
references.pmid: 12193025
references.citation: J Nat Prod. 2006 Dec;69(12):1676-9
references.pmid: 17190441
references.citation: J Nat Prod. 2004 Oct;67(10):1736-9
references.pmid: 15497952
references.citation: J Nat Prod. 2002 Jan;65(1):2-6
references.pmid: 11809054
references.citation: J Nat Prod. 2005 Sep;68(9):1416-9
references.pmid: 16180827
references.citation: J Nat Prod. 2004 May;67(5):921-4
references.pmid: 15165168
references.citation: Chem Pharm Bull (Tokyo). 2001 Oct;49(10):1372-4
references.pmid: 11605676
references.citation: J Nat Prod. 2005 Dec;68(12):1782-4
references.pmid: 16378375
references.citation: J Nat Prod. 2000 Oct;63(10):1369-72
references.pmid: 11076554
references.citation: J Nat Prod. 1994 Apr;57(4):528-33
references.pmid: 8021654
references.citation: Chem Pharm Bull (Tokyo). 1993 May;41(5):989-91
references.pmid: 8339346
references.citation: J Nat Prod. 2005 Aug;68(8):1253-5
references.pmid: 16124771
references.citation: J Nat Prod. 2003 Jan;66(1):2-6
references.pmid: 12542334
references.citation: J Nat Prod. 2009 Nov;72(11):2069-71
references.pmid: 19943625
references.citation: Life Sci. 2005 Dec 22;78(5):442-53
references.pmid: 16236327
references.citation: J Nat Prod. 2000 Apr;63(4):452-6
references.pmid: 10785412
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references.pmid: 2359136